Last reviewed · How we verify

NCT07291609: CCS-Plastics

Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes

Recruiting now Last updated 18 December 2025
What this trial tests

trial in Chronic Coronary Syndrome in 120 participants. Currently enrolling.

Timeline
1 September 2025
Primary endpoint
31 December 2026
31 December 2029

Quick facts

Lead sponsorAzienda Ospedaliera "Sant'Andrea"
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment120
Start date1 September 2025
Primary completion31 December 2026
Estimated completion31 December 2029
Sites6 locations across Italy

Conditions studied

Sponsor

Azienda Ospedaliera "Sant'Andrea" — full company profile →

Who can join

18 and older, any sex, with Chronic Coronary Syndrome or Microplastics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The CCS-plastics is an investigator-initiated, prospective, multicenter study of patients undergoing coronary CT angiography (CCTA) for suspected or known chronic coronary syndromes (CCS) referred to invasive coronary angiography for clinical indication. Patients identified as eligible for the protocol will be asked for written consent to participate in the study. The patients' dossiers will be uploaded and transmitted to the core laboratory for analysis. The routine management of the CCS patients will not be affected and all patients will be managed according to current standards. Invasive coronary angiography and coronary blood samples will be performed following the current standards, guidelines, and indications. During invasive coronary angiography, coronary blood samples will be collected per standard of care and sent to a centralized, specialized core laboratory for MNPs and biomarkers analysis. The central core lab for MNPs analyses will be the University of Campania Luigi Vanvitelli, Naples, Italy. The identification, quantification (concentration, mcg/ml), and typing of plastic particles will be performed in each tube for each patient, using pyrolysis-gas chromatography-mass spectrometry (Py-GC/MS) and laser direct infrared (LDIR) spectroscopy. The CCTA will be centrally analyzed by Centro Cardiologico Monzino to evaluate qualitative and quantitative plaque features. Patients will be followed clinically at 1 and 3 years per standard of care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Coronary Syndrome

Currently open trials in the same condition.

Other Azienda Ospedaliera "Sant'Andrea" trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07291609.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing